Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study-Reference-Cited by-同舟云学术

Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study

Published:2020-08-03 Issue:5 Volume:112 Page:674-689
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ito Ayumu,Kim Sung-Won,Matsuoka Ken-ichi,Kawakita Toshiro,Tanaka Takashi,Inamoto Yoshihiro,Toubai Tomomi,Fujiwara Shin-ichiro,Fukaya Masafumi,Kondo Tadakazu,Sugita Junichi,Nara Miho,Katsuoka Yuna,Imai Yosuke,Nakazawa Hideyuki,Kawashima Ichiro,Sakai Rika,Ishii Arata,Onizuka Makoto,Takemura Tomonari,Terakura Seitaro,Iida Hiroatsu,Nakamae Mika,Higuchi Kohei,Tamura Shinobu,Yoshioka Satoshi,Togitani Kazuto,Kawano Noriaki,Suzuki Ritsuro,Suzumiya Junji,Izutsu Koji,Teshima Takanori,Fukuda Takahiro

Funder

the National Cancer Center Research and Development Fund

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-020-02960-4.pdf

Reference43 articles.

1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet (Engl). 2002;359:2065–71.

2. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the lymphoma working party of the European group for blood and marrow transplantation. Haematologica. 2012;97:310–7.

3. Kako S, Izutsu K, Kato K, Kim SW, Mori T, Fukuda T, et al. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Am J Hematol. 2015;90:132–8.

4. Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: a retrospective analysis of the lymphoma working party of the european group for blood and marrow transplantation. Ann Oncol. 2016;27:2251–7.

5. Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2016;51:521–8.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan;International Journal of Hematology;2024-03-23

2. Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

3. Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma;Immuno-Oncology and Technology;2023-12

4. Checkpoint inhibition in hematologic malignancies;Frontiers in Oncology;2023-10-17

5. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study;Blood Advances;2023-10-13